Biology subjects

Sisk-Hackworth, L.

Publications and source records attributed to Sisk-Hackworth, L..

3 recordsLinked to original sources

bioRxiv2023

Hypogonadal (Gnrh1hpg) mice reveal niche-specific influence of reproductive axis and sex on intestinal microbial communities

The gut microbiome has been linked to many diseases with sex bias including autoimmune, metabolic, neurological, and reproductive disorders. Numerous studies report sex differences in fecal microbial communities, but how this differentiation occurs remains unclear. Using a genetic hypogonadal mouse model that does not produce sex steroids or go through puberty, we investigated how sex and the reproductive axis impact bacterial diversity within the small and large intestine. Both sex and reproductive axis inactivation altered bacterial composition in an intestinal section and niche-specific manner. Our results also implicated factors independent of the reproductive axis (i.e., sex chromosomes) in shaping intestinal communities. Additionally, our detailed profile of intestinal communities showed that fecal samples do not reflect bacterial diversity in the small intestine. Our results have ramifications for studying the impact of sex differences on the gut microbiome, particularly in sex-biased diseases and factoring in sex and steroid levels in microbial-based therapies.

microbiology↗

bioRxiv2019

Inhibition of both mutant and wild-type RAS-GTP in KRAS G12C colorectal cancer through cotreatment with G12C and EGFR inhibitors

The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we reveal a new benefit of this combination: it effectively inhibits both wild-type and mutant RAS. A role for WT RAS inhibition has not previously been reported for this important combination of targeted therapies. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.

cancer biology↗

bioRxiv2018

A Systems Mechanism for KRAS Mutant Allele Specific Responses to Targeted Therapy

A well-established genotype to phenotype relationship in genomic medicine is that activating KRAS mutations indicate resistance to anti-EGFR agents. We used a computational model of Ras signaling to investigate a confusing exception to this relationship whereby colorectal cancers with one specific, constitutively-active, mutant, KRAS G13D, respond to anti-EGFR agents. Our computational simulations of the biochemical processes that regulate Ras suggest EGFR inhibition reduces wild-type Ras activation in KRAS G13D mutant cancer cells more than in other KRAS mutant cancer cells. The model also reveals a non-intuitive, mutant-specific, dependency of wild-type Ras activation on EGFR. This dependency is determined by the interaction strength between a KRAS mutant and tumor suppressor neurofibromin. Our prospective experiments confirm this mechanism that arises from the systems-level regulation of Ras pathway signaling. Overall, our work demonstrates how systems approaches enable mechanism-based inference in genomic medicine.

cancer biology↗